Anti-Allergy Medicine Global Market Report 2025

The anti-allergy medicine market size has grown strongly in recent years. It will grow from $38.84 billion in 2024 to $42.25 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. This growth during the historic period can be credited to the increasing number of allergic conditions, heightened public awareness about allergy management, wider availability of over-the-counter allergy remedies, better access to healthcare services, and advancements in allergy diagnostic tools.

The anti-allergy medicine market size is expected to see strong growth in the next few years. It will grow to $58.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. Factors driving future growth include a rising global allergy burden, growing preference for rapid-relief medications, an aging population prone to allergies, the proliferation of e-pharmacy platforms, and enhanced governmental support for allergy education. Key trends expected in the market include innovations in drug delivery technologies, the emergence of non-drowsy antihistamines, advancements in customized allergy treatments, expanded R&D in biologic therapies, and the use of digital tools for managing allergic conditions.

The increasing prevalence of allergies is anticipated to drive the growth of the anti-allergy medicine market. Allergies are hypersensitive immune responses to allergens such as pollen, dust mites, certain foods, or pet dander, and can cause symptoms ranging from mild irritation to severe, potentially life-threatening reactions. These include hay fever, asthma, eczema, food allergies, and allergic rhinitis. The rise in allergy cases is largely attributed to growing environmental pollution, which can weaken the immune system and increase sensitivity to common allergens. Anti-allergy medicines provide targeted relief from these allergens, making them essential for managing conditions like hay fever, asthma, and eczema. These medications work by blocking histamines and other triggers, reducing immune overreactions and enhancing daily comfort and quality of life. For example, in November 2024, the Centers for Disease Control and Prevention reported that the number of people with asthma in the United States increased from 24,963,874 in 2021 to 26,799,588 in 2022. This rise in asthma cases underscores the expanding need for effective allergy treatments and supports the growth of the anti-allergy medicine market.

Key players in the anti-allergy medicine market are concentrating on the development of innovative therapies and obtaining regulatory approvals, such as monoclonal antibody treatments, to offer more targeted care, enhance treatment outcomes, reduce side effects, and address severe allergic conditions. Monoclonal antibody therapies are laboratory-engineered proteins designed to mimic the immune system’s function by targeting and blocking specific immune pathways involved in allergic responses. This provides more precise and sustained symptom relief. For instance, in December 2024, Galderma SA, a pharmaceutical company based in Switzerland, received FDA approval for Nemluvio (nemolizumab-ilto) to treat adults and children aged 12 and older with moderate to severe atopic dermatitis. Used in combination with topical corticosteroids or calcineurin inhibitors, this monoclonal antibody acts as an interleukin-31 receptor antagonist, blocking IL-31 signaling - an important factor in inflammation and itching associated with atopic dermatitis - thereby helping improve skin condition and reduce symptoms.

In January 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for $850 million. This acquisition was intended to bolster Johnson & Johnson’s immunology portfolio by incorporating Proteologix’s bispecific antibody programs, which are being developed to treat immune-mediated diseases such as atopic dermatitis and asthma. Proteologix Inc. is a biotechnology company in the United States that focuses on anti-allergy treatments using novel bispecific antibody therapies to target conditions like asthma and atopic dermatitis.

Major players in the anti-allergy medicine market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd., ALK-Abelló A/S, Torii Pharmaceutical Co. Ltd., Biomay Aktiengesellschaft, Kaléo Inc., Immunomic Therapeutics Inc., Circassia Group plc, Sun Pharmaceutical Industries Ltd., Anergis S.A., Aravax Pty Ltd., DBV Technologies S.A., and Desentum Oy.

North America was the largest region in the anti-allergy medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-allergy medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-allergy medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anti-allergy medicine encompasses a wide range of pharmaceutical products formulated to prevent or ease symptoms triggered by allergic reactions. These medications work by targeting the immune system's response to allergens such as pollen, dust mites, pet dander, insect bites, specific foods, and drugs. They help alleviate discomfort by addressing symptoms like sneezing, itching, nasal congestion, hives, and watery eyes.

The primary categories of anti-allergy drugs include antihistamines, corticosteroids, decongestants, leukotriene receptor antagonists, mast cell stabilizers, and other related classes. Antihistamines function by blocking the action of histamine, a compound released by the immune system during allergic responses. These are used to manage various allergy types, including seasonal, perennial, food, skin, and insect bite allergies. Based on formulation, these medicines are available as tablets, capsules, syrups, nasal sprays, eye drops, and injectables. Distribution channels include online pharmacies, hospitals, retail pharmacies, clinics, and others, and they cater to diverse end-user groups such as children, adults, the elderly, and pregnant individuals.

The anti-allergy medicine market research report is one of a series of new reports that provides anti-allergy medicine market statistics, including the anti-allergy medicine industry global market size, regional shares, competitors with the anti-allergy medicine market share, detailed anti-allergy medicine market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-allergy medicine industry. These anti-allergy medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anti-allergy medicine market consists of sales of combination therapies, inhalers, nebulizers, auto-injectors, prefilled syringes, and transdermal patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.